Cell Therapy News

NEW ORLEANS — Idecabtagene vicleucel induced initial complete remission in nearly half of patients with multiple myeloma who had early relapse after front-line therapy, results of a cohort analysis of the phase 2 KarMMa-2 trial showed.

The FDA granted fast track and regenerative medicine advanced therapy designations to CB-010, a chimeric antigen receptor T-cell therapy, for the treatment of relapsed or refractory B-cell non-Hodgkin lymphoma.

In this edition, lung cancer screening critically low across the U.S, first in-human CRISPR test with gene replacement, racial and economic segregation linked to higher cancer mortality rates, and more.

For the second time in the last 2 years, a drug related to the administration of cellular therapy — fludarabine — has been placed on the FDA’s drug shortage list.

Despite data on the approach still being accumulated, a panel of experts at Chemotherapy Foundation Symposium predicted that chimeric antigen receptor T cells will become front-line therapy for multiple hematologic malignancies.

The first personalized cellular therapy to use gene replacement for treatment of cancer has shown to be safe in solid tumors, data from a phase 1 study published at Society for Immunotherapy of Cancer Annual Meeting showed.

A novel monocyte-derived cell therapy showed evidence of migrating from the blood to the tumor microenvironment for several solid tumor types, according to phase 1 study results.

Matthew Matasar, MD, MS, has been named chief of blood disorders at Rutgers Cancer Institute of New Jersey and RWJBarnabas Health.

A single dose of lifileucel conferred an objective response in nearly one-third of patients with advanced unresectable or metastatic melanoma, results from the phase 2 C-144-01 trial showed.

Treatment with CTX130, a novel chimeric antigen receptor T-cell therapy, led to disease control in more than three quarters of patients with advanced clear cell renal cell carcinoma, results from a phase 1 trial showed.